Gabon vs Suriname: Access to anti-retroviral drugs, female
Gabon
63.0%
in 2024
Suriname
62.0%
in 2024
Gabon rank
96th
Suriname rank
99th
Access to anti-retroviral drugs, female over time
- Gabon
- Suriname
How they compare
Gabon currently reports 63.0% against 62.0% in Suriname, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Suriname ahead.
Gabon ranks 96th and Suriname ranks 99th of 141 countries.
Suriname has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Gabon | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 6.9% | 9.0% | 2.1% | Suriname |
| 2010s | 36.7% | 43.9% | 7.2% | Suriname |
| 2020s | 53.4% | 58.8% | 5.4% | Suriname |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Gabon or Suriname?
- Gabon, at 63.0% against 62.0% in Suriname as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Gabon and Suriname?
- 1.0%, with Gabon ahead.
- How many years of comparable data are there for Gabon and Suriname?
- 25 years are reported by both, from 2000 to 2024.
- How do Gabon and Suriname rank globally for access to anti-retroviral drugs, female?
- Gabon ranks 96th and Suriname ranks 99th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.